Tag: patients

LONDON, June 25, 2026 /PRNewswire/ -- Circulate Health and Reborne have today announced an exclusive partnership that will see Reborne become the first UK hospital...

SAN FRANCISCO, June 24, 2026 /PRNewswire/ -- The global digital health market is expected to witness significant expansion over the coming years, with the...

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

Hosted free by Pharmacy Stars on June 25, eight Camino Compass faculty, led by Principal Faculty Jocelyn Freimuth, PharmD, MBA, BCSCP, will put 64...

Legacy clears New York's stringent pre-market review of laboratory-developed tests for both of its core andrology assays, semen analysis and DNA fragmentation analysis.NEW YORK,...

SUMMIT, N.J., June 24, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful...

Global awareness campaign highlights the importance of genetic diagnosis in an era of rapidly advancing genetic medicineLOS ANGELES, June 24, 2026 /PRNewswire/ -- As...

Collaboration focuses on improving efficiency across the enterprise utilizing AI with tangible outcomes across IT, hospital operations and clinical supportBENGALURU, India and NORFOLK, Va.,...

VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head...

Telehealth program combines licensed medical care, insurance coordination, coaching and multiple prescription pathways for eligible patients

Telehealth program combines licensed medical care, insurance coordination, coaching and multiple prescription pathways for eligible patients